Association of remdesivir treatment with long-term mortality after COVID-19 hospitalization
In this real-world analysis of three large health systems in Colorado and Utah, RDV use was associated with decreased long-term mortality among survivors of initial COVID-19 hospitalization. Inpatient RDV treatment may provide a mortality benefit after COVID-19 hospitalization.
Authors
- David Mayer (ORCID: https://orcid.org/0000-0002-6056-9771)
- Adit A. Ginde (ORCID: https://orcid.org/0000-0003-2325-206X)
- Neil R. Aggarwal (ORCID: https://orcid.org/0000-0002-0922-8824)
- Jennifer L. Peers
- Nichole E. Carlson (ORCID: https://orcid.org/0000-0003-0679-6663)
- Trisha Agarwal
- Laurel Beaty (ORCID: https://orcid.org/0000-0001-8021-7872)
- Brandon Webb (ORCID: https://orcid.org/0000-0002-1799-3315)
- Tellen D. Bennett (ORCID: https://orcid.org/0000-0003-1483-4236)
- Kyle C. Molina (ORCID: https://orcid.org/0000-0002-6764-5984)
- Lindsey E. Fish (ORCID: https://orcid.org/0000-0003-2931-0654)
- Mengli Xiao (ORCID: https://orcid.org/0000-0003-4974-3588)
Institutions
- Intermountain Healthcare (US)
- Colorado School of Public Health (US)
- Denver Health Medical Center (US)
- University of Colorado Anschutz Medical Campus (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- BMC Infectious Diseases
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1186/s12879-025-11860-z
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- National Center for Advancing Translational Sciences